MedTrace Logo

Study for Recalcitrant Age Related Macular Degeneration

NCT01543568 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2017-01-02

Study results available
· View outcomes & findings →

Summary

50 Patients with recalcitrant exudative age-related macular degeneration with a history of retinal or subretinal fluid after multiple intravitreal injections with ranibizumab 0.5mg and subsequently treated with ranibizumab 2.0mg, who are incomplete responders to 2.0mg of ranibizumab.

Conditions

  • Age Related Macular Degeneration

Interventions

DRUG

aflibercept 2.0 mg

Intravitreal aflibercept injection 2.0 mg

Sponsors & Collaborators

Principal Investigators

  • David M Brown, MD · Director Greater Houston Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-10-31
Completion
2014-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01543568 on ClinicalTrials.gov